South San Francisco, CA October 4, 2023 Press Release Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment RAINBOWFISH study met its primary endpoint with 80% of…
South San Francisco, CA March 20, 2023 Press Release New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) Data…
South San Francisco, CA May 7, 2019 Genentech Press Release Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the 2019 AAN Annual Meeting In the dose-finding Part 1 of FIREFISH, infants with…